Desjardins Analysts Reduce Earnings Estimates for TSE:INO

Inovalis Real Estate Investment Trust (TSE:INO) – Equities research analysts at Desjardins decreased their Q2 2025 EPS estimates for shares of Inovalis Real Estate Investment Trust in a research note issued on Wednesday, May 14th. Desjardins analyst A. Leon now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.02.

Inovalis Real Estate Investment Trust Stock Performance

About Inovalis Real Estate Investment Trust

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.